Magnesium Infusion in Post-spinal Opioid PruritisNCT04160598
Effect of Intravenous Magnesium on Post-spinal Fentanyl Induced Pruritus Incidence
A study testing IV infusion and intrathecal fentanyl in people with Magnesium Infusion in Post-spinal Opioid Pruritis, run by Mansoura University at 1 site in Egypt.
Trial summary
Introduction: Adding opioids to local anesthetic solutions leads to enhanced anesthesia and provide postoperative analgesia. Intrathecaly injected opioids have some side effects, though. One of them is pruritus. Read more about this study
- Who is it for?
- Ages 20 to 70 years
- Conditions the study is for
- Magnesium Infusion in Post-spinal Opioid Pruritis
- What is being tested?
- IV infusion and intrathecal fentanyl
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 144 participants
- Where
- 1 siteEgypt
- Study dates
- 2 Sep 2020to 30 Mar 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ASA I-II Both genders Aged 20-70 years old Patient's candidate for LL orthopedic operations under spinal anesthesia
Who cannot join
- BMI>35 Patient refusal Hypersensitivity to amide local anesthetics Fentanyl opioids Magnesium and naloxone. Patients with LBBB and trifacicular block General contraindications to spinal anesthesia surgeon total refusal Cardiac, hepatic, renal or respiratory failure Difficult communication with the patient (psychological or deafness).
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Anesthesia department,Faculty of medicine, Mansoura univerisety
Al Mansurah, Dakahlia Governorate
mohamed ghanem, a.prof, 00201067883998, mohamed.abdel_latif@yahoo.com
About this study
Official title: Effect of Intravenous Magnesium on Post-spinal Fentanyl Induced Pruritus Incidence; A Prospective Randomized Controlled Study
Introduction: Adding opioids to local anesthetic solutions leads to enhanced anesthesia and provide postoperative analgesia. Intrathecaly injected opioids have some side effects, though. One of them is pruritus. Objective: We designed a randomized, double-blinded, placebo-controlled study to evaluate prophylactic impact of continuous IV Magnesium 10mg/kg over 30 minutes on intrathecal fentanyl-induced pruritus start at the end of the operation.
Methods: ASA I-II Patient's candidate for orthopedic operations under spinal anesthesia (10-15mg hyperbaric bupivacaine and 25 µg fentanyl intrathecal) and will be divided randomly into two groups:
Read more
Control group (Placebo group): bolus 100 ml nacl 0.9% at end of surgery Study group (Mg ++ group): (continuous IV Magnesium 10mg/kg in 100 ml Nacl0.9% over 30 minutes at end of surgery).
Study outcome:
- Hemodynamics: Systolic blood pressure, Mean arterial blood pressure, pulse rate, O2 saturation will be recorded in 5 min,10 min,30 min,60 min and every one hour till 6 hours after the operation.
- Pruritus Patients were asked about existence (present=1,no=0), severity (mild=1, modret=2, sever =3) and site of pruritus (Face(trigeminal) =1, neuroaxial(dermatome)=2), 1,2,4, and 6 hours after operation. Incidence of pruritus total group incidence %.
- The incidence of PONV.
Read the detailed description
Study hypothesis Intravenous Magnesium would reduce and improve post-spinal fentanyl pruritus incidence outcome relaying up on the fact that Magnesium ions block the neuroaxial NMDA receptor which are involved in histamine-induced expansion of mechanical receptive field area, a neural event possibly involved in the development of pruritis. (36) Aim of the work To introduce Magnesium sulphate as cheap effective alternative for prevention and management of post-spinal opioid pruritis.
Methods This prospective randomized double blinded controlled study will be carried out in Mansoura faculty of medicine in Mansoura University hospital on cases subjected to LL orthopedic operations under spinal anesthesia utilizing bupivacaine plus adjuvant fentanyl which is documented to have high incidence of postspinal pruritus.
Patients: ASA I-II, of both genders, aged 20-70 years old Patient's candidate for LL orthopedic operations under spinal anesthesia. Total patient number of 144, will be enrolled into two groups 72 patients each, all patients will be anesthetized intrathecaly using10-15mg hyperbaric bupivacaine and 30 µg fentanyl and will be subdivided randomly into two groups:
Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
Study group (MG++ Group): continuous IV infusion pump of Magnesium 10mg/kg in 50 ml Nacl0.9% over 20 minutes at end of surgery 5ml/minute infusion rate.
Randomization and blindness; the study drugs were prepared in 50 ml saline syringe according to the study randomization envelop method by an anesthesiologist who did not participate in the care and evaluation of the patients. The investigator and the patients were not aware of the drug they received.
Study outcomes (were assessed by the same clinician who cared for the patients in the perioperative and postoperative periods.)
- Demographic data Age weight, length, BMI, operative type and operative time.
- Hemodynamics: Systolic blood pressure, mean arterial blood pressure, heart rate, O2 saturation will be recorded basal, 10 min, 30 min, 60 min and every one hour till 6 hours after operation then every 6 h for the 1st 12 h after surgery.
- Pruritus Primary outcome =Incidence of pruritus in each group incidence %. Includes 3 items 1. Existence (present=1, no=0), 2. Severity (mild=1, modret=2, sever =3) 3. Site of pruritus (Face (trigeminal) =1, neuraxial (dermatome) =2) during the 1st 6 hours after spinal fentanyl injection.
- PO 1st 24 h Magnesium dose.
- PO 1st 24 h Naloxone.
- The incidence of PO vomiting% in each group. -Exclusion Criteria: BMI>35, Patient refusal, Hypersensitivity to amide local anesthetics, Fentanyl opioids, Magnesium and naloxone. Patients with coagulopathy, hepatic failure, LBBB and trifacicular block, General contraindications to spinal anesthesia, surgeon total refusal, Cardiac, hepatic, renal or respiratory failure, Difficult communication with the patient (psychological or deafness).
Side effects Management:
- Residual Sever pruritus after the 1st magnesium bolus will be controlled 1st by 2 second postoperative 10mg/kg dose of magnesium bolus IV if not controlled within one hour Naloxone bolus dose of 0.4 mg then if pruritus attack not controlled another 0.4 mg naloxone in 100ml normal saline iv infusion over the next 1hour during the postoperative 12 hours.
- Moderate Abdominal Pain: VAS >4 during surgical manipulation is unaccepted and managed soon using multimodal analgesia regimen including; ketorolac slow injection in an IV bolus of 0.5mg/kg if general anesthesia needed to control pain case will be excluded from the study.
- Nausea \& Vomiting: treated by metoclopramide 10 mg, if resistant IV bolus ondansetron 4mg, with treatment of hypotension if present.
- Hypotension (mean arterial blood pressure (MAP) less than 65 mmHg, will be managed by using ephedrine bolus doses of 6mg, fluids and blood transfusion according to events and requirements.
- Bradycardia (HR less than 60 b/m.) will be managed by atropine bolus of 0.5 mg.
- Desaturation (SaO2< 90%) will be managed by increase oxygen face mask flow up to 10 L/sec. and dealing with the airway according to the situation targeting a patient airway with breathing comfort and O2saturation>94% In case of any respiratory depression, emergency airway equipment's and drugs for resuscitation for airway management and ventilation were kept ready.
- Sample size calculation Sample size was calculated using Power Analysis and Sample Size software program (PASS) version 15.0.5 for windows (2017) using the results published by [S.S. Jahanbakhsh and S. Bazyar. Study on prophylactic impact of ondansetron IV on intrathecal fentanyl-induced pruritus. British Journal of Anesthesia 108 (S2): ii387-ii437 (2012) doi:10.1093/bja/aer489] (37) With the incidence of post-operative opioid induced pruritis after spinal anesthesia as the primary outcome. Patients will be allocated into two groups: control group (placebo Group) and the study group (MG++ Group). Jahanbakhsh 2012 resulted in post-spinal fentanyl induced pruritus incidence of 34% ondansetron group versus 60% in the placebo group. The null hypothesis is assumed to be the absence of difference between both treatment modalities. A sample of 65 patients is in each group needed to achieve 80% power (1-β or the probability of rejecting the null hypothesis when it is false) to detect a difference between the group proportions of 26% using two-sided Fisher's exact test with a significance level of 0.05(α or the probability of rejecting the null hypothesis when it is true). The expected number of dropouts is 7 patients in each group so 72 patients will be enrolled into each group with a total study sample size number of 144 patients.
Statistical analysis IBM's SPSS Statistics (Statistical Package for the Social Sciences) for Windows (version 25) will be used for statistical analysis of the collected data. Shapiro-Wilk test will be used to check the normality of the data distribution. Normally distributed continuous variables will be expressed as mean ± SD while categorical variables and the abnormally distributed continuous ones will be expressed as median and inter-quartile range or number and percentage (as appropriate). Student t-test and Mann-Whitney will be used for normally and abnormally distributed continuous data respectively. Chi-square tests will be used for categorical data using the crosstabs function. All tests will be conducted with a 95% confidence interval. If needed, bivariate correlations will be assessed using Pearson's or Spearman's correlation coefficient depending on the nature of data. P (probability) value < 0.05 will be considered statistically significant.
- Being tested
- IV infusion, intrathecal fentanyl
- Keywords
- Neuraxial opioids, post-operative itching, intrathecal Fentanyl pruritus, Spinal anesthesia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IV infusionDrug
Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
intrathecal fentanylDrug
10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected
| Study group | Role | What they receive |
|---|---|---|
| Placebo group | Placebo comparator | bolus 50 ml nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate. Receives: Drug: IV infusion; Drug: intrathecal fentanyl |
| IV Mg ++ group | Experimental | continuous IV infusion pump of Magnesium 10mg/kg in 50 ml Nacl0.9% over 20 minutes at end of surgery 5ml/minute infusion rate. Receives: Drug: IV infusion; Drug: intrathecal fentanyl |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of pruritus in each group incidence %.
Existence,Severity, Site of pruritus (Face (trigeminal) =1, neuraxial (dermatome) =2)
Measured: during the 1st 6 hours after spinal fentanyl injection.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Nov 2019
- Study start2 Sep 2020
- Primary completion20 Mar 2021 (estimated)
- Study completion30 Mar 2021 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Magnesium Infusion in Post-spinal Opioid PruritisStudies of the same condition, open and under way.
- More trials run by Mansoura UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 144 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mansoura University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Abd Latif Ghanim, Mansoura University
- Investigators
- mohamed ghanem, Study chair, Mansoura Faculty of Medicine-Mansoura University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04160598
- Sponsor's protocol ID
- R.19.09.628.R1.R2
- Status last verified
- Sep 2020
- First submitted
- 9 Nov 2019
- Last updated
- 4 Sep 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Intravenous Magnesium on Post-spinal Fentanyl Induced Pruritus Incidence; A Prospective Randomized Controlled Study
- ClinicalTrials.gov ID
- NCT04160598
- Acronym / sponsor ID
- R.19.09.628.R1.R2
- Keywords
- Neuraxial opioids, post-operative itching, intrathecal Fentanyl pruritus, Spinal anesthesia
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 144 participants (estimated)
- Lead sponsor
- Mansoura UniversityUniversity, hospital or other
- Study start
- 2 Sep 2020 (actual)
- Primary completion
- 20 Mar 2021 (estimated)
- Study completion
- 30 Mar 2021 (estimated)
- First posted
- 13 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Introduction: Adding opioids to local anesthetic solutions leads to enhanced anesthesia and provide postoperative analgesia. Intrathecaly injected opioids have some side effects, though. One of them is pruritus. Objective: We designed a randomized, double-blinded, placebo-controlled study to evaluate prophylactic impact of continuous IV Magnesium 10mg/kg over 30 minutes on intrathecal fentanyl-induced pruritus start at the end of the operation.
Methods: ASA I-II Patient's candidate for orthopedic operations under spinal anesthesia (10-15mg hyperbaric bupivacaine and 25 µg fentanyl intrathecal) and will be divided randomly into two groups:
Control group (Placebo group): bolus 100 ml nacl 0.9% at end of surgery Study group (Mg ++ group): (continuous IV Magnesium 10mg/kg in 100 ml Nacl0.9% over 30 minutes at end of surgery).
Study outcome:
- Hemodynamics: Systolic blood pressure, Mean arterial blood pressure, pulse rate, O2 saturation will be recorded in 5 min,10 min,30 min,60 min and every one hour till 6 hours after the operation.
- Pruritus Patients were asked about existence (present=1,no=0), severity (mild=1, modret=2, sever =3) and site of pruritus (Face(trigeminal) =1, neuroaxial(dermatome)=2), 1,2,4, and 6 hours after operation. Incidence of pruritus total group incidence %.
- The incidence of PONV.
Detailed description
Study hypothesis Intravenous Magnesium would reduce and improve post-spinal fentanyl pruritus incidence outcome relaying up on the fact that Magnesium ions block the neuroaxial NMDA receptor which are involved in histamine-induced expansion of mechanical receptive field area, a neural event possibly involved in the development of pruritis. (36) Aim of the work To introduce Magnesium sulphate as cheap effective alternative for prevention and management of post-spinal opioid pruritis.
Methods This prospective randomized double blinded controlled study will be carried out in Mansoura faculty of medicine in Mansoura University hospital on cases subjected to LL orthopedic operations under spinal anesthesia utilizing bupivacaine plus adjuvant fentanyl which is documented to have high incidence of postspinal pruritus.
Patients: ASA I-II, of both genders, aged 20-70 years old Patient's candidate for LL orthopedic operations under spinal anesthesia. Total patient number of 144, will be enrolled into two groups 72 patients each, all patients will be anesthetized intrathecaly using10-15mg hyperbaric bupivacaine and 30 µg fentanyl and will be subdivided randomly into two groups:
Control group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate.
Study group (MG++ Group): continuous IV infusion pump of Magnesium 10mg/kg in 50 ml Nacl0.9% over 20 minutes at end of surgery 5ml/minute infusion rate.
Randomization and blindness; the study drugs were prepared in 50 ml saline syringe according to the study randomization envelop method by an anesthesiologist who did not participate in the care and evaluation of the patients. The investigator and the patients were not aware of the drug they received.
Study outcomes (were assessed by the same clinician who cared for the patients in the perioperative and postoperative periods.)
- Demographic data Age weight, length, BMI, operative type and operative time.
- Hemodynamics: Systolic blood pressure, mean arterial blood pressure, heart rate, O2 saturation will be recorded basal, 10 min, 30 min, 60 min and every one hour till 6 hours after operation then every 6 h for the 1st 12 h after surgery.
- Pruritus Primary outcome =Incidence of pruritus in each group incidence %. Includes 3 items 1. Existence (present=1, no=0), 2. Severity (mild=1, modret=2, sever =3) 3. Site of pruritus (Face (trigeminal) =1, neuraxial (dermatome) =2) during the 1st 6 hours after spinal fentanyl injection.
- PO 1st 24 h Magnesium dose.
- PO 1st 24 h Naloxone.
- The incidence of PO vomiting% in each group. -Exclusion Criteria: BMI>35, Patient refusal, Hypersensitivity to amide local anesthetics, Fentanyl opioids, Magnesium and naloxone. Patients with coagulopathy, hepatic failure, LBBB and trifacicular block, General contraindications to spinal anesthesia, surgeon total refusal, Cardiac, hepatic, renal or respiratory failure, Difficult communication with the patient (psychological or deafness).
Side effects Management:
- Residual Sever pruritus after the 1st magnesium bolus will be controlled 1st by 2 second postoperative 10mg/kg dose of magnesium bolus IV if not controlled within one hour Naloxone bolus dose of 0.4 mg then if pruritus attack not controlled another 0.4 mg naloxone in 100ml normal saline iv infusion over the next 1hour during the postoperative 12 hours.
- Moderate Abdominal Pain: VAS >4 during surgical manipulation is unaccepted and managed soon using multimodal analgesia regimen including; ketorolac slow injection in an IV bolus of 0.5mg/kg if general anesthesia needed to control pain case will be excluded from the study.
- Nausea \& Vomiting: treated by metoclopramide 10 mg, if resistant IV bolus ondansetron 4mg, with treatment of hypotension if present.
- Hypotension (mean arterial blood pressure (MAP) less than 65 mmHg, will be managed by using ephedrine bolus doses of 6mg, fluids and blood transfusion according to events and requirements.
- Bradycardia (HR less than 60 b/m.) will be managed by atropine bolus of 0.5 mg.
- Desaturation (SaO2< 90%) will be managed by increase oxygen face mask flow up to 10 L/sec. and dealing with the airway according to the situation targeting a patient airway with breathing comfort and O2saturation>94% In case of any respiratory depression, emergency airway equipment's and drugs for resuscitation for airway management and ventilation were kept ready.
- Sample size calculation Sample size was calculated using Power Analysis and Sample Size software program (PASS) version 15.0.5 for windows (2017) using the results published by [S.S. Jahanbakhsh and S. Bazyar. Study on prophylactic impact of ondansetron IV on intrathecal fentanyl-induced pruritus. British Journal of Anesthesia 108 (S2): ii387-ii437 (2012) doi:10.1093/bja/aer489] (37) With the incidence of post-operative opioid induced pruritis after spinal anesthesia as the primary outcome. Patients will be allocated into two groups: control group (placebo Group) and the study group (MG++ Group). Jahanbakhsh 2012 resulted in post-spinal fentanyl induced pruritus incidence of 34% ondansetron group versus 60% in the placebo group. The null hypothesis is assumed to be the absence of difference between both treatment modalities. A sample of 65 patients is in each group needed to achieve 80% power (1-β or the probability of rejecting the null hypothesis when it is false) to detect a difference between the group proportions of 26% using two-sided Fisher's exact test with a significance level of 0.05(α or the probability of rejecting the null hypothesis when it is true). The expected number of dropouts is 7 patients in each group so 72 patients will be enrolled into each group with a total study sample size number of 144 patients.
Statistical analysis IBM's SPSS Statistics (Statistical Package for the Social Sciences) for Windows (version 25) will be used for statistical analysis of the collected data. Shapiro-Wilk test will be used to check the normality of the data distribution. Normally distributed continuous variables will be expressed as mean ± SD while categorical variables and the abnormally distributed continuous ones will be expressed as median and inter-quartile range or number and percentage (as appropriate). Student t-test and Mann-Whitney will be used for normally and abnormally distributed continuous data respectively. Chi-square tests will be used for categorical data using the crosstabs function. All tests will be conducted with a 95% confidence interval. If needed, bivariate correlations will be assessed using Pearson's or Spearman's correlation coefficient depending on the nature of data. P (probability) value < 0.05 will be considered statistically significant.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo group | Placebo comparator | Drug: IV infusion, Drug: intrathecal fentanylbolus 50 ml nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate. |
| IV Mg ++ group | Experimental | Drug: IV infusion, Drug: intrathecal fentanylcontinuous IV infusion pump of Magnesium 10mg/kg in 50 ml Nacl0.9% over 20 minutes at end of surgery 5ml/minute infusion rate. |
Who may qualify
- Ages
- 20 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- ASA I-II Both genders Aged 20-70 years old Patient's candidate for LL orthopedic operations under spinal anesthesia
Key exclusion criteria (1 listed)
- BMI>35 Patient refusal Hypersensitivity to amide local anesthetics Fentanyl opioids Magnesium and naloxone. Patients with LBBB and trifacicular block General contraindications to spinal anesthesia surgeon total refusal Cardiac, hepatic, renal or respiratory failure Difficult communication with the patient (psychological or deafness).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IV infusionControl group (Placebo Group): bolus 50 ml Nacl 0.9% at the end of surgery over 20 minutes 5ml/minute infusion rate. | Drug | IV Mg ++ group, Placebo group |
| intrathecal fentanyl10-15mg hyperbaric bupivacaine and 30µg fentanyl intrathecally injected | Drug | IV Mg ++ group, Placebo group |
Primary outcome
Incidence of pruritus in each group incidence %.
Time frame: during the 1st 6 hours after spinal fentanyl injection.
Existence,Severity, Site of pruritus (Face (trigeminal) =1, neuraxial (dermatome) =2)
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2020.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
mohamed ghanem study chair
Mansoura Faculty of Medicine-Mansoura University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing IV infusion and intrathecal fentanyl in people with Magnesium Infusion in Post-spinal Opioid Pruritis, run by Mansoura University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact mohamed Ghanem, A.professor (00201067883998, mohamed.abdel_latif@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of pruritus in each group incidence %. (time frame: during the 1st 6 hours after spinal fentanyl injection.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2020.